semaglutide and kidney problems in patients with overweight or obesity chronic disease without diabetes: a randomized double-blind placebo-controlled clinical trial semaglutide and chronic kidney disease

Internal Accolade document

What the research shows (& what it doesnt) Potential Benefits Many people lose a significant amount of weight (up to 15% of body weight in some trials) Appetite often decreases, sometimes dramatically Improvements in measures of blood glucose management, cholesterol, and blood pressure have been observed during clinical trials But here's whats also true: Known Risks and Gaps in Knowledge Short-term research : Most studies last no longer than 1-2 years

However, that meta-analysis included only nine studies (seven RCTs and two cohort studies), did not evaluate the risk of bias of included studies, nor did it report data on kidney outcomes

Mounjaro is designed to act on the bodys hunger control mechanisms, helping users manage their appetite more effectively

Another recommends 500mcg

This difference in dose strength and frequency is key to how quickly results appear